InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,713.64
(
1.70%
)
US TECH 100
19,316.00
(
2.43%
)
Dow Jones
42,025.19
(
1.26%
)
Brent Oil
74.32
(
2.68%
)
Bitcoin
62,970.74
(
2.11%
)
Post# of 253159
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120470
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 238314

Friday, 07/16/2021 6:42:10 PM

Friday, July 16, 2021 6:42:10 PM

Post# of 253159
FDA approves MRK’s Vaxneuvance—(f/k/a V114)—pneumococcal vaccine_for_adults:

https://www.merck.com/news/merck-announces-u-s-fda-approval-of-vaxneuvance-pneumococcal-15-valent-conjugate-vaccine-for-the-prevention-of-invasive-pneumococcal-disease-in-adults-18-years-and-older-caused-by-15-serot/

Vaxneuvance will compete against PFE’s Prevnar-20, which was FDA-approved for adults a few weeks ago (#msg-164292101).

This is a very large market that could play out as “winner takes all.” PFE has an edge, IMO.

Please see #msg-164292101 for background info on these products.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up